Episode Details
Back to Episodes
Pharmaceutical Executive Daily: FDA Extends Review of Leqembi's sBLA
Published 1 week, 5 days ago
Description
In today’s Pharmaceutical Executive Daily, the FDA extends its priority review of a subcutaneous formulation of Leqembi, industry analysts examine how upcoming GLP-1 patent expirations could reshape the drug delivery device market, and experts discuss the key forces driving renewed growth in radiopharmaceuticals.